Cellnovo announces the launch of the first clinical study in the EU. The 4-month clinical study will include 15 patients in centres in London (UK) and Girona (Spain). The recently CE-marked next-generation Cellnovo System, the industry’s first Bluetooth and Android-enabled micro-pump for insulin delivery, will serve as the central platform of the PEPPER solution. You can find the full press relsease here.